Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Urothelial Carcinoma Treatment Market size was valued at USD 1.47 billion in 2024 and is set to exceed USD 17.9 billion by 2037, expanding at over 21.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of urothelial carcinoma treatment is evaluated at USD 2.01 billion.
The growth of the market can be attributed to the increasing incidence of bladder cancer worldwide. Further, in terms of prevalence, bladder cancer ranks 10th around the globe. Men have nearly four times more chances than women to have bladder cancer. Smoking poses the biggest risk for bladder cancer, as tobacco contains carcinogens, which are poisons, and are known to cause cancer. Long-term smoking causes your kidneys to filter these poisons into urine before they enter your bloodstream. According to estimates, there are more than 1 billion smokers globally. This number is projected to increase to 2 billion over the next 20 years.
In addition to these, factors that are believed to fuel the market growth of urothelial carcinoma treatment include the excessive use of analgesics. Analgesics are commonly known as "painkillers," which are used to treat a variety of pains, including headaches, injuries, and arthritis. Painkillers are safe however, they might have unfavorable side effects and difficulties if taken too regularly, for too long, or in very large doses. Further, urinary tract cancer and atherosclerosis disease are two additional severe consequences that can result from long-term strong painkiller usage. For instance, painkiller usage is the most typical cause of bladder cancer in women under the age of 50.
Urothelial Carcinoma Treatment Sector: Growth Drivers and Challenges
Growth Drivers
-
Increasing Healthcare Strategies – The top market players have employed a variety of methods that are fostering market growth. For instance, the introduction of newer technologies such as the Internet of Things and remote observation, artificial intelligence, big data analytics, blockchain, intelligent wearables, and others supports the health ecosystem, as well as improvements in medical diagnosis, data-based treatment decisions, digital therapeutics, clinical trials, self-management of care, and person-centered care, have all been shown to improve health outcomes. By 2026, 40% of all IoT-driven devices will be utilized in the health and wellness sector.
-
Rising Funding for Research and Development to Develop Novel Cancer Therapies – Drug development is being fueled by significant investment in the field of cancer therapy. Many scientific advancements have resulted from this developing field of study. The creation of new treatments that have enhanced patient outcomes and have the potential to increase patient lifespans by months or years. The US Food and Drug Administration authorized more than 60 of 355 novel therapeutic medicines and biologic compounds between 2009 and 2018.
-
Growing Drug Approvals for Cancer– Better treatments receiving approval from prestigious drug regulatory agencies are anticipated to be advantageous for the market for urothelial cancer medications. In 2021, more than 200 cancer drugs were approved in oncology and malignant hematology.
-
Rising Awareness Regarding Early Diagnosis of Cancer – Knowledge about malignancies and cancer screening measures will aid in an earlier diagnosis, more effective treatment, and better results. Early intervention involves delivering care at the earliest time feasible. A reduced likelihood of survival, more treatment-related issues, and a higher cost of care are all consequences of delayed or unavailable cancer therapy. The American Cancer Society estimates that the 5-year relative survival rate is more than 90% for breast cancer that is diagnosed early, and in the localized stage.
Challenges
-
Adverse effects of chemotherapy - Drugs circulate throughout the body and can impact healthy, normal cells as well as those that are rapidly dividing. There are adverse consequences when healthy cells are damaged. For instance, certain chemotherapy medications can harm the cells in the nervous system, heart, kidneys, bladder, and lungs. While some adverse effects may take months or even years to entirely disappear, many of them do so rather rapidly.
-
Expensive equipment is needed for urothelial carcinoma therapy
- The high cost of R&D expenditure for the creation of a new medicine for treatment
Urothelial Carcinoma Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
21.2% |
|
Base Year Market Size (2024) |
USD 1.47 billion |
|
Forecast Year Market Size (2037) |
USD 17.9 billion |
|
Regional Scope |
|
Urothelial Carcinoma Treatment Segmentation
Treatment (Immunotherapy, Radiotherapy, Chemotherapy
The global urothelial carcinoma treatment market is segmented and analyzed for demand and supply by treatment into immunotherapy, radiotherapy, and chemotherapy. Out of the three types of treatments, the chemotherapy segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the introduction of more chemotherapeutic drugs which are being approved for use in the urothelial carcinoma treatment. Clinical trials are being conducted on a variety of systemic chemotherapies to determine which medicines or medication combinations are most effective at treating bladder cancer. The majority of the time, a pharmacological cocktail is more effective than a single medication. For instance, the use of cisplatin-based chemotherapy prior to major surgery for muscle-invasive bladder cancer is firmly supported by scientific research. Cisplatin is a chemotherapy drug used which is usually used to treat testicular, ovarian, bladder, head and neck, lung, and cervical cancer. In 2018, approximately 10 million out of 17 million new cases of cancer required chemotherapy globally.
End-user (Hospital Pharmacy, Retail Pharmacy)
The global urothelial carcinoma treatment market is also segmented and analyzed for demand and supply by end-user into hospital pharmacy, retail pharmacy, and others. Amongst these three segments, the hospital pharmacy segment is expected to garner a significant share. Hospitals are a critical part of the healthcare business and a significant source of revenue for the whole sector, which supports research and innovation. A hospital's uses cutting-edge medical technology to address complex medical situations. It is simpler and more convenient for patients with cancer or other diseases to acquire the recommended medications right on the hospital grounds when they are receiving treatment. On the other hand, private hospitals are increasingly being seen as needed to increase their specialization and cater to patients who need urgent medical attention, such as cancer and cardiovascular treatment.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Urothelial Carcinoma Treatment Industry - Regional Synopsis
North American Market Forecast
North America industry is set to account for largest revenue share of 38% by 2037. The growth of the market can be attributed majorly to the increasing frequency of urothelial carcinoma cancer in the region. Cigarette smoking continues to be the largest cause of avoidable illness, disability, and death in the area. There are presently more than 30 million adult smokers in the US. Additionally, males smoke more frequently than females do, and black people smoke more frequently than white people. Furthermore, in the USA, smoking has a significant negative economic impact. The majority of the direct costs associated with tobacco use come from medical expenses to treat associated diseases and lost productivity as a result of sickness and early mortality. Every year, bladder cancer causes 17,000 fatalities and 80,000 new cases in the United States.
Europe Market Forecast
The European urothelial carcinoma treatment market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the increasing incidence of urothelial cancer in various European economies. Among the 28 European Union member states, bladder cancer affects more than 120 000 individuals each year (EU). It is the sixth most common cancer cause, taking the lives of more than 40 000 people each year. For instance, owing to a higher frequency of smoking and an older population, incidence rates of bladder cancer have been rising in Germany and Bulgaria, and are predicted to continue rising. Additionally, in Germany, 3-4% of all malignant tumors are bladder carcinomas, and around 15,000 individuals are diagnosed with bladder cancer each year, making it the fourth most frequent malignancy among males. They are more common in those over the age of 70. Moreover, there has been a rising number of bladder cancer cases, including metastatic bladder cancer, that is further anticipated to rise the market’s growth in the region. Further, Southern Europe has the greatest prevalence of bladder cancer among females.
Companies Dominating the Urothelial Carcinoma Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Novartis AG
- Dendreon Pharmaceuticals LLC
- Sanofi SA
- F. Hoffmann-La-Roche AG
- UroGen Pharma Ltd
- Koninklijke Philips N.V.
- Olympus Corporation
- AstraZeneca PLC
Recent Developments
-
Olympus Corporation announced a binding agreement to purchase London-based cloud-AI endoscopy business Odin Vision, which offers a wide range of commercially available computer-aided detection/diagnostic (CAD) solutions. With the agreement, Olympus is able to provide cutting-edge AI-powered solutions and data-driven insights that improve clinical and procedural procedures and change patient care.
-
Sanofi SA licensed an NK cell engager program from Innate's ANKETTM (Antibody-based NK Cell Engager Therapies) technology that targets B7H3. This extended partnership with Innate Pharma will enable Sanofi to have the option of including up to two more ANKETTM targets, and be in control of all development, manufacture, and marketing.
- Report ID: 3912
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
